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Abstract
Background: The elevated serum and peritoneal cytokine concentrations responsible for the
systemic response syndrome (SIRS) and multiorgan failure in patients with severe acute pancreatitis
lead to high morbidity and mortality rates. Prompted by reports underlining the importance of
reducing circulating inflammatory mediators in severe acute pancreatitis, we designed this study to
evaluate the efficiency of laparotomy followed by continuous perioperative peritoneal lavage
combined with postoperative continuous venovenous diahemofiltration (CVVDH) in managing
critically ill patients refractory to intensive care therapy. As the major clinical outcome variables
we measured morbidity, mortality and changes in the Acute Physiology and Chronic Health
Evaluation (APACHE II) score and cytokine concentrations in serum and peritoneal lavage fluid
over time.
Methods: From a consecutive group of 23 patients hospitalized for acute pancreatitis, we studied
6 patients all with Apache II scores ≥19, who underwent emergency surgery for acute
complications (5 for an abdominal compartment syndrome and 1 for septic shock) followed by
continuous perioperative peritoneal lavage and postoperative CVVDH. CVVDH was started within
12 hours after surgery and maintained for at least 72 hours, until the multiorgan dysfunction
syndrome improved. Samples were collected from serum, peritoneal lavage fluid and CVVDH
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cytokine levels was assessed.
Results: All six patients tolerated CVVDH well, and the procedure lasted a mean 6 days (range,
3-12). Five patients survived and one died of Acinetobacter infection after surgery (mortality rate
16.6%). The mean APACHE II score was ≥ 19 (range 19-22) before laparotomy and decreased
significantly during peritoneal lavage and postoperative CVVDH (P = 0.013 by matched-pairs
Students t-test). The decrease in cytokine concentrations in serum and lavage fluid was associated
with the decrease in APACHE II scores and high interleukin 6 (IL-6) and tumor necrosis factor
(TNF) concentrations in the hemofiltrate.
Conclusion: In critically ill patients with abdominal compartment syndrome, septic shock or high
APACHE II scores related to severe acute pancreatitis, combining emergency laparotomy with
continuous perioperative peritoneal lavage followed by postoperative CVVHD effectively reduces
the local and systemic cytokines responsible for multiorgan dysfunction syndrome thus improving
patients' outcome.
Background
In patients with severe acute pancreatitis (SAP), the pri-
mary cause of morbidity, mortality and high costs is the
multiorgan dysfunction syndrome (MODS) [1,2]. Accu-
mulating evidence underlines the relationship between
sepsis, systemic multiorgan damage (lung, liver, kidney,
and heart) and elevated serum and peritoneal concentra-
tions of cytokines (IL-1, IL-6, IL-8, IL-10) and tumor
necrosis factor (TNF) [3-12]. A procedure known to
reduce plasma cytokine levels is continuous venovenous
diahemofiltration (CVVDH) [13,14]. As well as purifying
the blood, hemofiltration has a major adjunctive thera-
peutic role as immunomodulatory therapy in sepsis
[15,16]. The high levels of inflammatory mediators
(cytokines and others) found not only in serum but also
in peritoneal fluid from patients with SAP underline the
importance of reducing cytokine levels in the SAP-related
systemic inflammatory response syndrome (SIRS)
[2,17,18].
In 20-30% of patients manifestingprogressive multiorgan
failure, intensive care treatment fails and mortality
reaches 40% [19]. In these critically ill patients, severe
complications such as abdominal compartment syn-
drome or sepsis often necessitate emergency laparotomy
[20,21]. Prompted by reports underlining the importance
of reducing circulating inflammatory mediators in severe
acute pancreatitis [3,22-28], we conjectured that perito-
neal and systemic cytokine concentrations could be
reduced by combining emergency laparotomy with con-
tinuous perioperative peritoneal lavage with postopera-
tive CVVDH. Lowering local and systemic cytokine
toxicity might thus reduce morbidity and mortality in
acute pancreatitis.
Our aim in this preliminary single-center study was to
find out whether in a small series of selected critically ill
patients with SAP refractory to ICU therapy a new
approach comprising emergency laparotomy to resolve
abdominal compartment syndrome or sepsis followed by
continuous perioperative peritoneal lavage to remove
local cytokines and postoperative CVVDH to reduce sys-
temic cytokines would benefit patients' outcome. As out-
come variables we evaluated postoperative IL-6 and TNF
concentrations in serum, peritoneal lavage outflow and
CVVDH filtrate and sought an association between their
decrease and changes in the clinical progression of SAP
over time as measured by APACHE II scores.
Methods
We studied 23 consecutive patients with acute pancreatitis
diagnosed according to the Italian Association for the
Study of the Pancreas (AISP) criteria [29]. The severity of
acute pancreatitis was classified according to the Atlanta
criteria [30]. The major cause of acute pancreatitis was bil-
iary disease (20 patients) followed by alcohol (2 patients)
and hyperlipidemia (1 patient). Of the 23 patients
enrolled, 18 had mild acute pancreatitis but 5 had severe
acute pancreatitis on presentation. According to the Balt-
hazar computed tomographic (CT) criteria for grading
acute pancreatitis [31] 12 patients were in grade C, 8 in
grade D and 3 in grade E (severe pancreatitis).
At admission all patients underwent standard medical
therapy according to the guidelines of the Italian Associa-
tion for the Study of the Pancreas (AISP) [32] including
fluid resuscitation, gastrointestinal decompression, oxy-
gen therapy, parenteral nutritional support, somatostatin,
antibiotics (imipenem-cilastatin) and infusion of the
enzyme inhibitor gabexate mesilate (900 mg/day). Of the
23 initial participants, 17 patients responded well to med-
ical therapy and were discharged after a mean 13 days. The
remaining 6 patients (2 men and 4 women; mean age
60.8 years, range 27-74) whose clinical conditions failedPage 2 of 7
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had an Apache II score of ≥ 19. These 6 patients under-
went emergency laparotomy, 5 for an abdominal com-
partment syndrome, defined as a susteined
intraabdominal pressure about 20 mmHg associated with
new organ failure, and 1 for septic shock. At surgery the
anterior pancreatic wall was widely exposed, the capsule
fully opened and Kocher's maneuver was used to mobilize
the pancreatic head and body anteriorly. The pancreatic
body and tail were then manually freed starting from the
Treitz ligament. Eventual necrotic tissue and fluid collec-
tions were sampled for microbiological cultures and
removed. Patients with acute biliary pancreatitis under-
went cholecystectomy and a biliary drain was placed
through the cystic duct. To allow complete lavage, drains
were placed close to the anterior and posterior pancreatic
walls, in the paracolic gutters and pelvis. A lavage solution
containing 6 to 8 liters of normal saline and gabexate
mesilate (1000 mg) was perfused through the drains every
24 hours for at least 7 days.
After surgery all six patients were admitted to the ICU and
CVVDH was started within 12 hours. For vascular access,
a double coaxial lumen 14-Fr catheter was inserted percu-
taneously through the right internal jugular or femoral
vein using the Seldinger technique. A Baxter BM25 system
(Baxter, USA) was used for CVVDH with a polyacryloni-
trile NA69 hemofilter (1.2 m2surface area, 35-kD limit;
Hospal, USA). Blood flow was set at 50-75 ml/min and
ultrafiltrate flow at 1000 ml/h, transmembrane pressure
was maintained between 450-460 mmHg, and the
replacement fluid was pre-diluted and infused. Low-
molecular-weight heparin was used as the anticoagulant,
patient-activated clotting time was adjusted to 60-70 sec-
onds, and a strictly neutral balance was maintained using
a digital balance system (Baxter). CVVDH was maintained
for a mean 6 days (range 3-8). The AN69 hemofilter (1.2
m2) was changed every 24 hours.
Samples for measuring cytokine concentrations were col-
lected from serum at admission (T0) and 48 hours later
(T48). After surgery, samples were taken also from perito-
neal lavage fluid and hemofiltrate on postoperative days
I, IV, VII, and XIV. The last sample was collected when
CVVDH ended. IL-6 and TNF were assayed with an
enzyme-linked immunosorbent assay (ELISA) kit using
the quantitative immunoenzymatic sandwich method.
Vital signs, including body temperature, breath rate,
blood pressure and heart rate were recorded half hourly.
Blood samples were collected every 24 hours to monitor
blood cell counts, serum amylase and electrolytes, liver
and kidney function, and arterial blood gases. As an out-
come variable, APACHE II scores were determined daily to
evaluate the patients' clinical conditions and were
matched with IL-6 and TNF concentrations in serum and
lavage fluid. The other outcome variables assessed were
surgical morbidity and mortality.
Statistical analysis
Results are expressed as mean ± SD and data for the two
continuous outcome variables were analyzed using Stu-
dent's matched-pairs t-test. Differences were considered
significant at P < 0.05.
Results
Of the six patients with severe acute pancreatitis who had
emergency laparotomy followed by continuous perioper-
ative peritoneal lavage with postoperative CVVDH, five
were cured and discharged from hospital. One patient
died of septic shock related to Acinetobacter infection
(surgical mortality 16.6%). None of the patients had
major surgery-related complications during the postoper-
ative course except an enteric fistula that developed in 1
patient and responded to conservative therapy with pro-
longed total parenteral nutrition. The mean hospital stay
was 28.5 days, and 13.3 days in the ICU. Cultures of
microbiological samples taken during surgery grew Ente-
rococcus in 2 cases, Escherichia coli in 2, Pseudomonas in
1 and no infection in another.
IL-6 and TNF concentrations were high in serum before
surgery (T0, Figure 1, panel A and B) and in peritoneal
fluid on postoperative day I (Figure 1, panel C and D) but
decreased rapidly during peritoneal lavage (Figure 1, pan-
els A, B, C and D). Over the same time course, IL-6 and
TNF concentrations in the hemofiltrate increased (Figure
1, panel E).
The other outcome variable, the mean Apache II score
measuring patients' worsening clinical conditions,
increased from 8 at admission to 19.6 at 48 hours to 23
on postoperative day I when CVVDH began. Conversely,
it decreased significantly during peritoneal lavage and
CVVDH (from 18.6 on postoperative day IV to 8 after the
second postoperative week) (P = 0.013) as patients' clini-
cal conditions improved over time. Over the same time
course, IL-6 and TNF concentrations in serum remained
statistically unchanged (P = 0.07 and P = 0.309) but in
peritoneal lavage fluid decreased significantly (P = 0.019
and 0.008), whereas hemofiltrate TNF concentrations
alone increased (P = 0.03) (Figure 1, panel E). Student's t-
test for matched pairs disclosed a significant association
between decreasing cytokine concentrations in serum and
peritoneal lavage fluid and decreasing Apache II scores
(Figure 1, panel A-E).
The only CVVDH-related adverse reaction was a high fever
caused by an infected catheter that resolved when the
catheter was removed. Hypophosphatemia developed inPage 3 of 7
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Panel A and BFigure 1
Panel A and B. Note the high IL-6 and TNF serum concentrations before surgery (T0 and T48) and the rapid decrease during 
peritoneal lavage and continuous venovenous diahemofiltration (CVVDH). APACHE II scores improved significantly from T48 
to the end of CVVDH (p = 0.013 by matched-paired Student's t-test) whereas IL-6 and TNF concentrations decreased over 
the same time course though not significantly. Panel C and D. The decrease in IL-6 and TNF concentration in peritoneal lavage 
fluid became significant (P = 0.019 and P = 0.008) between the two time-points T48 and when CVVDH ended and was signifi-
cantly associated with the decrease in APACHE II scores over the same time course (P = 0.013). Panel E. Note the high IL-6 
and TNF concentrations in the hemofiltrate, suggesting that continuous venovenous diahemofiltration (CVVDH) effectively 
purified these patients' sera.
World Journal of Emergency Surgery 2009, 4:45 http://www.wjes.org/content/4/1/45two patients and was normalized by increasing the phos-
phate content in the CVVDH dialitic solution.
Discussion
Our promising results in this single-center preliminary
study in selected severely ill patients refractory to ICU
therapy suggest that the new approach we propose, emer-
gency laparotomy to resolve abdominal compartment
syndrome or sepsis followed by continuous perioperative
peritoneal lavage and postoperative CVVDH, successfully
reduces local and systemic cytokines thus reducing mor-
bidity and mortality and improving patients' clinical out-
come without increasing the high surgery-related
morbidity.
All six patients with SAP in this series had high APACHE
II scores before surgery, indicating MODS [33] and they
also had severe SAP-related complications, in five patients
an abdominal compartment syndrome and in one sepsis,
all refractory to ICU therapy and therefore necessitating
emergency surgery. In patients with SAP, the inflamma-
tory response (SIRS) to extensive peripancreatic and retro-
peritoneal fatty tissue damage, may lead to sepsis, acute
respiratory distress syndrome (ARDS), acute renal failure,
hypovolemic shock, acute liver failure and MODS, now
the primary cause of morbidity and mortality in SAP [13].
In accordance with their severe clinical presentation,
MODS and multiorgan failure, all our patients with SAP
had high perioperative IL-6 and TNF concentrations in
serum, peritoneal lavage outflow and CVVDH hemofil-
trate, presumably related to pro-inflammatory cytokine
release and neutrophil activation [22,23]. Although we
measured only IL-6 and TNF, other inflammatory media-
tors known to play a critical role in acute pancreatitis and
MODS include TNFa, IL-1b, IL-6, IL-8, platelet-activating
factor, and IL-10 [3,22-28].
Our study extends to the few therapeutic options for
removing the inflammatory mediators responsible for
SAP-related systemic complications [33]. In all 6 patients
we treated, anti-inflammatory therapy using continuous
perioperative peritoneal lavage and postoperative CVVDH
effectively reduced IL-6 and TNF concentrations in perito-
neal lavage fluid and serum. Continuous hemofiltration
(CHF), especially CVVDH, was developed for patients in
severe conditions and has been used mainly in critical care
[34,35]. CVVDH can remove many inflammatory media-
tors, includingTNF, IL-1, IL-6, sIL-2R, IL-8, IL-2 and IL-10
all having a molecular weight lower than 50000 Daltons
[1,36-40]. CVVDH also helped to normalize our patients'
water, electrolyte and acid-base balance and homeostasis
related to renal dysfunction.
In line with others, we provide further evidence that con-
tinuous perioperative peritoneal lavage reduces cytokine
concentrations in the abdominal cavity and diminishes
their systemic absorption thus halting the progression of
SIRS and MODS [2,18]. The higher the cytokine concen-
trations in the peritoneal cavity the greater is the quantity
absorbed into the blood. In an experimental model of
acute pancreatitis Mikami et al found increased IL-1β and
TNF-α levels in the lavage fluids in all models during the
first 6 hours after induction, and the peak levels accorded
with the severity of pancreatitis [18]. In a large study,
including 577 patients, Dugerneir et al observed signifi-
cantly lower mortality for acute pancreatitis in patients
who underwent surgical treatment with postoperative
peritoneal lavage than in others who had surgery alone
(mortality 24.3% vs 43.2%) [2]. An early study already
showed that peritoneal lavage had a role in the treatment
of acute pancreatitis even before "cytokine storm" became
a recognized feature in the pathogenesis of acute pancrea-
titis [41].
By diluting local peritoneal cytokine concentrations as
well as reducing serum reabsorbtion, peritoneal lavage
during laparotomy with or without necrosectomy fol-
lowed by CVDDH presumably had a dual advantage,
interfering at two distinct levels in the cytokine-related
pathophysiological mechanisms in patients with SAP.
When we investigated the association between IL-6 and
TNF values in peritoneal lavage fluid and serum and
changes in the clinical progression of SAP over time as
measured by APACHE II scores, we found elevated
APACHE II scores (more than 19) in patients whose
serum and peritoneal fluid contained high concentrations
of IL-6 and TNF. Conversely, as serum and peritoneal IL-6
and TNF levels decreased our patients' clinical conditions
progressively improved (Figure 1, panels A and D) The
predicted mortality rate in patients with high APACHE II
scores was actually considerably higher than the observed
rate (42% vs 16.6%).
During laparotomy, to resolve our patients' life-threaten-
ing SAP-related complications, we widely opened the ret-
roperitoneal space and mobilized the pancreas thus
extending the surface available for peritoneal cytokine lav-
age. Although this complex procedure led to no immedi-
ate or postoperative complications, the abdominal drains
might possibly have caused the abdominal Acinetobacter
infection in the patients who died. Conversely, the enteric
fistula observed in one case, probably depended on diffi-
culty in dissecting adherences related to a previous surgi-
cal intervention.
Whether adding gabexate mesilate to the peritoneal lavage
fluid helped to reduce inflammatory mediators in the
peritoneal cavity remains unclear. We were prompted to
try this inexpensive, non-toxic expedient by evidence from
our previous experimental and clinical studies [42,43]
showing that this enzyme inhibitor acts directly on pan-Page 5 of 7
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activity.
Conclusion
The new approach we propose for reducing the circulating
cytokines responsible for systemic damage in patients
with SAP -- emergency laparotomy followed by continu-
ous perioperative peritoneal lavage and postoperative
CVVDH -- is challenging for surgeons, patients and care-
takers. In specialized centers, it should nevertheless have
a useful place in treating selected critically ill patients with
SAP refractory to ICU therapy for whom emergency sur-
gery is needed. By eliminating the local peritoneal
cytokines responsible for the development of SIRS and at
the same time reducing systemic circulating cytokines
from the serum, this management option offers a lower
mortality rate than expected and an acceptable clinical
outcome. This combined management strategy warrants
confirmation in randomized control trials.
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